1-3 of 3
Sarah C. Rutherford
Close
Sort by
Journal Articles

Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphoma

Clinical Trials & Observations
Sarah C. Rutherford, Jun Yin, Levi D. Pederson, Kristie A. Blum, Peter Martin, Sin-Ho Jung, Barbara Grant, Cara Rosenbaum, Bruce D. Cheson, Nancy L. Bartlett, Sumithra J. Mandrekar, John P. Leonard
Journal: Blood Advances
Blood Adv (2024) 8 (6): 1464–1468.
https://doi.org/10.1182/bloodadvances.2023012090
Published: 2024
Includes: Supplemental data
Journal Articles

Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma

Clinical Trials & Observations
Michael Dickinson, Javier Briones, Alex F. Herrera, Eva González-Barca, Nilanjan Ghosh, Raul Cordoba, Sarah C. Rutherford, Eirini Bournazou, Emily Labriola-Tompkins, Izolda Franjkovic, Evelyne Chesne, Jurriaan Brouwer-Visser, Katharina Lechner, Barbara Brennan, Eveline Nüesch, Mark DeMario, Dominik Rüttinger, Martin Kornacker, Martin Hutchings
Journal: Blood Advances
Blood Adv (2021) 5 (22): 4762–4770.
https://doi.org/10.1182/bloodadvances.2021004619
Published: 2021
Includes: Supplemental data
Journal Articles

Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA

Clinical Trials & Observations
Sarah C. Rutherford, Michael Herold, Wolfgang Hiddemann, Lale Kostakoglu, Robert Marcus, Maurizio Martelli, Laurie H. Sehn, Marek Trněný, Judith Trotman, Umberto Vitolo, Tina Nielsen, Federico Mattiello, Deniz Sahin, Gila Sellam, Peter Martin
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1589–1593.
https://doi.org/10.1182/bloodadvances.2019001261
Published: 2020
Includes: Supplemental data